—of cherished memory—
KEVIN HANLON was President and CEO of ComSource, Inc., a technology systems integrator he co-founded in 1989 headquartered outside of Syracuse, New York. ComSource worked with many Global 500 companies supplying high performance technology infrastructure for enterprise data centers throughout central and eastern United States. Kevin earned a B.S. in Marketing and Business Administration from The University of Vermont and a Master’s in Business Administration from Syracuse University.
He is survived by his wife Denise and three children; Lilly, Mark and Ellrose. A lifetime runner, cyclist and triathlete, he competed in two Boston Marathons to benefit the Dana-Farber Cancer Institute and will be competing as a cyclist in the upcoming Dana-Farber Pan Mass Challenge.
Kevin was also an Eagle Scout and enthusiastically involved in Boy Scout leadership. His son Mark, is also working towards that achievement. Kevin and his family have been active members of Immaculate Conception Church for 52 years.
Kevin never smoked and his NSCLC EGFR exon 20 insertion diagnosis came as a shock. He and his brother Bob, founded the Exon 20 Group to shine a spotlight on, and accelerate the discovery and rapid approval of promising exon 20 targeted agents to the benefit of current and future NSCLC EGFR and HER2 exon 20 patients.
ROBERT HANLON, PHD is a Senior Lecturer in MIT’s Department of Chemical Engineering and is responsible for helping operate the School of Chemical Engineering Practice at locations around the globe. Prior to this, he had spent 23 years in industry, first with Mobil Oil Corporation where he was involved in the research and development of new catalyst technology, culminating in the 1997 commercialization of an all-catalytic lube oil process at Mobil’s oil refinery in Singapore.
MARCIA K. HORN, JD is the president and CEO of ICAN, International Cancer Advocacy Network, https://askican.org
At ICAN, Marcia is a research advocate who has directly navigated many thousands of complex cancer patient cases pan-tumor since the founding of the organization in 1996. She is also a molecular profiling advocate, a clinical trials matching advocate, an expanded access program advocate, a public policy advocate, and a health equity advocate.
Since March 2017, Marcia has served as the Executive Director of the Exon 20 Group (https://exon20group.org), an international multi-stakeholder coalition created to transform cancers caused by rare and lethal insertion mutations into manageable and survivable conditions. The Exon 20 Group provides more than 25 services to patients, care partners, and additional stakeholders and launched an International Research Consortium and developed plans for a Knowledge Bank project in 2021.
Marcia is one of the two research advocates selected for both the Stand Up 2 Cancer Molecular Early Detection of Colon Cancer Dream Team and the Stand Up 2 Cancer InTIME Dream Team for Lung Cancer Interception. She served for three years as DIA’s inaugural chairman of its Patient Engagement Community and is a PCORI Ambassador. Marcia is a member of the ASCO TAPUR Study Molecular Tumor Board, the Banner Health Institutional Review Board, and the SWOG Early Therapeutics/Rare Cancers Committee. She is a research advocate for the National Cancer Institute’s University of Texas Southwestern Medical Center Lung Cancer SPORE (Specialized Program of Research Excellence).
Marcia graduated Phi Beta Kappa from Stanford University in Political Science and received her JD from Stanford Law School. Before joining ICAN, she practiced litigation and appellate law in Phoenix and had major leadership roles in the arts and civic organizations in Arizona.